Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia

27 Sept 2018

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Viral Infectious Diseases and Gene Expression in Insects
Share to Virus-based gene therapy research

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 30275569
DOI: 10.1038/s41591-018-0146-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemiaPMID 30275569Read ↗

CAR therapy: the CD19 paradigmSemantic proximity Read ↗

CAR-T Cell TherapySemantic proximity Read ↗

Chimeric Antigen Receptor Based Cellular Therapy for Treatment Of T-Cell MalignanciesSemantic proximity Read ↗

Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell DysfunctionSemantic proximity Read ↗

TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearanceSemantic proximity Read ↗

Antigen experience history directs distinct functional states of CD8+ CAR T cells during the anti-leukemia responseSemantic proximity Read ↗

Design and Preclinical Development of a Novel In Vivo Chimeric Antigen Receptor (CAR) Product for B-Cell Involved DiseasesSemantic proximity Read ↗

Molecular monitoring of residual disease using antigen receptor genes in childhood acute lymphoblastic leukaemiaSemantic proximity Read ↗

Targeting HLA-DR loss in hematologic malignancies with an inhibitory chimeric antigen receptorSemantic proximity Read ↗

IKAROS facilitates antigen escape in the face of CD19- and CD22-targeted therapies for B-cell acute lymphoblastic leukemiaSemantic proximity Read ↗

Escape From ALL-CARTazSemantic proximity Read ↗

Tumor Antigen Escape from CAR T-cell TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.